Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mikkel Z Ankarfeldt, Brian L Thorsted, Rolf HH Groenwold, Erpur Adalsteinsson, M Sanni Ali & Olaf H Klungel. (2017) Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study. Clinical Epidemiology 9, pages 19-30.
Read now
Read now
Manjiri Pawaskar, Jinan Liu, Swapnil Rajpathak, Kristy Iglay, Samuel S. Engel & Hakima Hannachi. (2017) Demographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world setting. Current Medical Research and Opinion 33:7, pages 1247-1253.
Read now
Read now
Erin K. Buysman, Wing Chow, Henry J. Henk & Marcia F.T. Rupnow. (2015) Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Current Medical Research and Opinion 31:1, pages 137-143.
Read now
Read now
Nils Schoof, Janet Schnee, Gary Schneider, Melissa Gawlik, Kristina Zint, Andreas Clemens & Dorothee B. Bartels. (2014) Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Current Medical Research and Opinion 30:5, pages 795-804.
Read now
Read now
Andre Scheen. (2013) Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 12:4, pages 545-557.
Read now
Read now
John E. Anderson, Andrew S. Rhinehart, Timothy S. Reid, Robert M. Cuddihy, Aleksandra Vlajnic, Mehul R. Dalal, Eric Gemmen, Bryan Johnstone, Babak Abbaszadeh, Josh Reed, Jennifer Sheller, John Stewart & Essy Mozaffari. (2013) A Practice-Based Research Network Focused on Comparative Effectiveness Research in Type 2 Diabetes Management. Postgraduate Medicine 125:3, pages 172-179.
Read now
Read now
Articles from other publishers (12)
Fatema Mahmoud, Alexander Mullen, Chris Sainsbury, Gordon F. Rushworth, Haya Yasin, Nouf Abutheraa, Tanja Mueller & Amanj Kurdi. (2023) Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus. European Journal of Clinical Investigation 53:8.
Crossref
Crossref
Corinne Emery, Elodie Torreton, Sylvie Dejager, Laurie Levy-Bachelot, Sébastien Bineau & Bruno Detournay. (2020) Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database. Diabetes Therapy 11:2, pages 535-548.
Crossref
Crossref
Richard Ofori-Asenso, Jenni Ilomaki, K.L. Chin, Mohsen Mazidi, Ella Zomer, J.S. Bell, Dianna J. Magliano & Danny Liew. (2019) Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice 158, pages 107909.
Crossref
Crossref
Soulmaz Fazeli Farsani, Atsushi Taniguchi, Rie Ikeda, Kimberly G Brodovicz & Dorothee B Bartels. (2019) Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan. Journal of Diabetes Investigation 10:5, pages 1246-1253.
Crossref
Crossref
Tongtong Wang, Ann Marie McNeill, Yong Chen, Edward A. O’Neill & Samuel S. Engel. (2018) Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. Diabetes Therapy 9:1, pages 309-315.
Crossref
Crossref
Kazuya Fujihara, Risa Igarashi, Satoshi Matsunaga, Yasuhiro Matsubayashi, Takaho Yamada, Hiroki Yokoyama, Shiro Tanaka, Hitoshi Shimano, Hiroshi Maegawa, Katsuya Yamazaki, Koichi Kawai & Hirohito Sone. (2017) Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine 96:7, pages e6122.
Crossref
Crossref
Kazuya Fujihara, Osamu Hanyu, Yoriko Heianza, Akiko Suzuki, Takaho Yamada, Hiroki Yokoyama, Shiro Tanaka, Hiroaki Yagyu, Hitoshi Shimano, Atsunori Kashiwagi, Katuya Yamazaki, Koichi Kawai & Hirohito Sone. (2015) Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists. Journal of Diabetes Investigation 7:2, pages 260-269.
Crossref
Crossref
M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom & Vincent Lo ReIIIIII. (2015) Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacology and Toxicology 16:1.
Crossref
Crossref
Kimberly G. Brodovicz, Yong Chen, Zhiwen Liu, Mary E. Ritchey, Jane Liao & Samuel S. Engel. (2015) Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database. Diabetes Therapy 6:4, pages 627-634.
Crossref
Crossref
Jong-Mi Seong, Nam-Kyong Choi, Ju-Young Shin, Yoosoo Chang, Ye-Jee Kim, Joongyub Lee, Ju-Young Kim & Byung-Joo Park. (2015) Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study. PLOS ONE 10:5, pages e0124287.
Crossref
Crossref
K. G. Brodovicz, T. D. Kou, C. M. Alexander, E. A. O'Neill, M. Senderak, S. S. Engel & C. J. Girman. (2013) Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database. International Journal of Clinical Practice 67:5, pages 449-454.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Nephrology & Hypertension 20:5, pages 561-571.
Crossref
Crossref